The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Plasma triglyceride and coronary heart disease
Open accessAbstract
Although the literature on epidemiological associations between plasma triglyceride and CHD is not completely consistent, trends do emerge from the studies described here. First, the majority of observational studies demonstrate a significant univariate relation, although the results of case-control and cross-sectional studies are more uniform than those from prospective study designs. In many but not all studies, triglyceride remains a significant predictor of CHD in multivariate statistical analyses after controlling for TC or LDL-C. Perhaps the least consistent result is that the triglyceride association does not persist in some analyses controlling for HDL-C, while in other studies, the association remains significant. Although most studies have been conducted in men, the studies providing data on women, normocholesterolemic subjects, and diabetic subjects have generally found triglyceride to be, at the very least, a univariate risk factor. The results of intervention trials differ considerably, but no such study to date has been specifically designed to evaluate triglyceride-lowering effects on primary prevention of CHD. Important statistical properties must be taken into consideration in evaluating triglyceride as a risk factor for CHD. The large variability of triglyceride measurements and the correlation of triglyceride values with other lipid measures appears to result in the underestimation of the association between triglyceride and disease in multivariate analyses. Finally, individual genetic susceptibility may play an important role in the relation between plasma triglyceride levels and CHD. For example, risk of CHD clearly varies among the well-established familial forms of hypertriglyceridemia. A predominance of small, dense, LDL particles (LDL subclass pattern B) also appears to be a genetic trait associated with both increased risk of MI and increases in plasma triglyceride levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis.”
In the citing paper
“Over the past three decades, epidemiologic and genetic evidence has accumulated to support the concept that elevated levels of plasma TG, TRL, and TRL remnants are causally related to an increased risk of ASCVD-related events—myocardial infarction (MI), stroke, and aortic valve stenosis—and all-cause mortality.1,2,17,19,20,24–28”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Meade, T. W., Brozović, M., Chakrabarti, R., Haines, A., Imeson, J., Mellows, S., Miller, G. J., North, W. R. S., Stirling, Y., & Thompson, S. G. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90111-x · Cited by 1,937
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780
Self-citationMorbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study
Garcia, M. J., McNamara, P. M., Gordon, T., & Kannell, W. B. (1974) · Diabetes · doi:10.2337/diab.23.2.105 · Cited by 1,608
Castelli, W. P., Doyle, J. T., Gordon, T., Hames, C. G., Hjortland, M. C., Hulley, S. B., Kagan, A., & Zukel, W. J. (1977) · Circulation · doi:10.1161/01.cir.55.5.767 · Cited by 1,492
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., de Faire, U., Dahlén, G. H., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,444
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Self-citation
Flagged first, then by citations
Research works printed but not linked: 26
- [2]2. National Heart, Lung, and Blood Institute Consensus Development Panel: Treatment of hypertriglyceridemia. JAMA 1984;251:1196-1200
- [15]15. factors in relation to acute myocardial infarction. Arteriosclerosis 1981;1:273-279
- [30]30. Cambien F, Jacqueson A, Richard JL, Warnet JM, Ducimetiere P, Claude JR: Is the level of serum triglyceride a it,, ot f oo teir olemic" subjects? The Paris Prospective Study. Am J Epidemiol 1986;124:624-632
- [29]29. Carlson LA, Böttiger LÈ: Risk factors for ischaemic heart disease in men and women. Acta Med Scand 1985;218:207–211
- [32]32. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangiwala S: Triglycerides and coronary heart disease mortality: The Lipid Research Clinics Follow-up Study. Atheroscler Rev (in press)
- [34]34. Pocock SJ, Shaper AG, Phillips AN: Concentrations of high density lipoprotein cholesterol, triglyceride and total cholesterol in ischaemic heart disease. Br Med J 1989;298:998–1002
- [37]37. Wilson PF: The impact of triglycerides on coronary heart disease: The Framingham Study. Atherosclerosis Rev (in press)
- [4]4. Scand Suppl 1973;549:51–59
- [46]46. Salel AF, Riggs K, Mason DT, Amsterdam EA, Zelis R: The impdsie rea psie ia p psng factor in coronary artery disease. Am J Med 1974;57:897–903
- [50]50. Jenkins PJ, Harper RW, Nestel PJ: Severity of coronary atherosclerosis related to lipoprotein concentration. Br Med J 1978;2:388-391
- [53]53. Wieland H, Seidel D, Wiegand V, Kreuzer H: Serum lipoproteins and coronary artery disease (CAD). Atherosclerosis 1980;36:269-280
- [55]55. Holmes DR Jr, Elveback LR, Frye RL, Kottke BA, Ellefson RD: Association of risk factor variables and coronary artery disease documented with angiography. Circulation 1981;63: 293-299
- [58]58. Reardon MF, Nestel PJ, Craig IH, Harper RW: Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation 1985;71:881-888
- [64]64. Santen RJ, Willis PW, Fajaris SS: Atherosclerosis in diabetes mellitus: Correlations with lipid levels, adiposity and serum insulin level. Arch Intern Med 1972;130:833–843
- [66]66. Janka HU: Five-year incidence of major macrovascular complications in diabetes mellitus. Horm Metab Res Suppl Series 1985;15:15-19
- [71]71. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-374
- [77]77. Kelsey J, Thompson WD, Evans AS: Methods in Observational Epidemiology. New York, Oxford University Press, 1986, pp 293–297
- [84]84. Davis CE, Kim H: Is triglyceride an independent risk factor for CHD? Circulation 1990;81:14
- [88]88. Childs B: Introduction, in Childs B, Holtzman NA, Kazazian HH, Valle DL (eds): Molecular Genetics in Medicine. Progress in Medical Genetics, New Series, Vol 7. New York, Elsevier, 1988, Pp 1-16
- [93]93. Mahley RW, Innerarity TL, Rall SC Jr, Weisbraber KH: Lipoproteins of special significance in atherosclerosis: Insights provided by studies of Type III hyperlipidemia. Ann N Y Acad Sci 1986;485:209–221
- [92]92. Sane T, Nikkila EA: Very low density lipoprotein triglyceride metabolism in relatives of hypertriglyceridemic probands. Arteriosclerosis 1987;8:217–226
- [97]97. Shen MMS, Krauss RM, Lindgren FT, Forte TM: Heterogeneity of serum low density lipoproteins in normal subjects. J Lipid Res 1981;22:236–244
- [99]99. Lindgren FT, Jensen LC, Hatch FT: The isolation and quantitative analysis of serum lipoproteins, In Nelson GJ (ed): Blood Lipids and Lipoproteins. New York, Wiley Interscience, 1972, pp 181–274
- [101]101. Eisenberg S, Gavish D, Oschry Y, Fainaru M, Deckelbaum RJ: Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia. J Clin Invest 1984;74:470–482
- [102]102. Nichols AV, Krauss RM, Musliner TA: Nondenaturing polyacrylamide gradient gel electrophoresis, In Segrest JP, Albers JJ (eds): Methods in Enzymology, Plasma Lipoproteins. Part A. Preparation, Structure and Molecular Biology. Orlando, Fla, Academic Press, Inc, 1986, vol 41, pp 417–431
- [110]110. Gianturco SH, Bradley WA: A cellular basis for the atherogenicity of triglyceride-risk lipoproteins. Atherosclerosis Rev (in press)
Cited by
Sorted by citations
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
“, risk unrelated to its impact on LDL and HDL remodeling), but this issue remains debated (16, 223, 635).”
BackgroundNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
“Postmenopausal with HT NA NA NA NA 278 (15) 352 (18)c 326 (18)c 368 (19)b”
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Self-citationAbdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk
Després, J.-P., Lemieux, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E., Rodés-Cabau, J., Bertrand, O. F., & Poirier, P. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.159228 · Cited by 1,589
Grundy, S. M., Pasternak, R., Greenland, P., Smith, S., & Fuster, V. (1999) · Circulation · doi:10.1161/01.cir.100.13.1481 · Cited by 1,315
Metadata
- Authors
- Austin, M. A.
- Affiliations
- University of Washington (US)
- Corresponding author
- Austin, M A
- Venue
- Arteriosclerosis and Thrombosis: A Journal of Vascular Biology
- Published
- 1991-01
- Volume
- 11
- Issue
- 1
- Pages
- 2-14
- ISSN
- 1049-8834 (ISSN-L)
- OpenAlex
- W2155238815
- Cited by
- 697
- References
- 98
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 6 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 8 · 2015: 5 · 2014: 5 · 2013: 13 · 2012: 8
- FWCI
- 15.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis and Thrombosis A Journal of Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r29hl038760-03)
- National Heart, Lung, and Blood Institute (HL38760, P01HL030086, HL3-0086)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- plasma triglycerides, coronary artery disease, cardiovascular risk factors, hypertriglyceridemia, familial hypertriglyceridemia, small dense LDL, HDL cholesterol, genetic susceptibility, primary prevention, lipid-lowering intervention
- MeSH terms
- Coronary Disease, Female, Humans, Male, Pedigree, Triglycerides, Multivariate Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review